Literature DB >> 18283400

TNF-antagonist etanercept induced reversible posterior leukoencephalopathy syndrome.

Oliver Kastrup, Hans Christoph Diener.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18283400     DOI： 10.1007/s00415-008-0732-y

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  11 in total

Review 1.  Toxic leukoencephalopathy.

Authors:  C M Filley; B K Kleinschmidt-DeMasters
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

Review 2.  The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.

Authors:  Gerald Gartlehner; Richard A Hansen; Beth L Jonas; Patricia Thieda; Kathleen N Lohr
Journal:  J Rheumatol       Date:  2006-12       Impact factor: 4.666

3.  Granulocyte-stimulating factor filgrastim and molgramostim induced recurring encephalopathy and focal status epilepticus.

Authors:  O Kastrup; H C Diener
Journal:  J Neurol       Date:  1997-04       Impact factor: 4.849

4.  Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy.

Authors:  In-Sook J Shin; Alan N Baer; Hyon J Kwon; Elektra J Papadopoulos; Jeffrey N Siegel
Journal:  Arthritis Rheum       Date:  2006-05

Review 5.  Cyclosporine neurotoxicity: a review.

Authors:  J M Gijtenbeek; M J van den Bent; C J Vecht
Journal:  J Neurol       Date:  1999-05       Impact factor: 4.849

6.  Posterior reversible encephalopathy syndrome due to severe hypercalcemia.

Authors:  O Kastrup; M Maschke; I Wanke; H C Diener
Journal:  J Neurol       Date:  2002-11       Impact factor: 4.849

7.  Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier.

Authors:  Donald Wong; Katerina Dorovini-Zis; Steven R Vincent
Journal:  Exp Neurol       Date:  2004-12       Impact factor: 5.330

8.  Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases.

Authors:  R B Schwartz; S M Bravo; R A Klufas; L Hsu; P D Barnes; C D Robson; J H Antin
Journal:  AJR Am J Roentgenol       Date:  1995-09       Impact factor: 3.959

Review 9.  Optic neuritis occurring with anti-tumour necrosis factor alpha therapy.

Authors:  Ismail Simsek; Hakan Erdem; Salih Pay; Gungor Sobaci; Ayhan Dinc
Journal:  Ann Rheum Dis       Date:  2007-04-24       Impact factor: 19.103

Review 10.  New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous system.

Authors:  Sumio Ohtsuki
Journal:  Biol Pharm Bull       Date:  2004-10       Impact factor: 2.233
View more
  9 in total

1.  Case files of the New York City poison control center: paradichlorobenzene-induced leukoencephalopathy.

Authors:  Stephanie H Hernandez; Sage W Wiener; Silas W Smith
Journal:  J Med Toxicol       Date:  2010-06

Review 2.  Rheumatologic diseases and posterior reversible encephalopathy syndrome: two case reports and review of the literature.

Authors:  Anmol Dhillon; Celso Velazquez; Chokkalingam Siva
Journal:  Rheumatol Int       Date:  2012-07-24       Impact factor: 2.631

Review 3.  Eosinophilic granulomatosis with polyangiitis (EGPA) and PRES: a case-based review of literature in ANCA-associated vasculitides.

Authors:  A M Marra; G Barilaro; V Villella; M Granata
Journal:  Rheumatol Int       Date:  2015-04-03       Impact factor: 2.631

4.  Posterior Reversible Encephalopathy Syndrome: The Spectrum of MR Imaging Patterns.

Authors:  O Kastrup; M Schlamann; C Moenninghoff; M Forsting; S Goericke
Journal:  Clin Neuroradiol       Date:  2014-02-20       Impact factor: 3.649

5.  Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody.

Authors:  Brian H Kushner; Shakeel Modak; Ellen M Basu; Stephen S Roberts; Kim Kramer; Nai-Kong V Cheung
Journal:  Cancer       Date:  2013-04-30       Impact factor: 6.860

Review 6.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

7.  An Overview of The Role of Tumor Necrosis Factor-Alpha in Epileptogenesis and Its Terapeutic Implications.

Authors:  Alexandre Michev; Alessandro Orsini; Viola Santi; Francesco Bassanese; Daniele Veraldi; Ilaria Brambilla; Gian Luigi Marseglia; Salvatore Savasta; Thomas Foiadelli
Journal:  Acta Biomed       Date:  2022-03-21

8.  Tacrolimus associated posterior reversible encephalopathy syndrome - a case series and review.

Authors:  Susmitha Apuri; Kristin Carlin; Edward Bass; Phuong Thuy Nguyen; John N Greene
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-02-18       Impact factor: 2.576

9.  Targeting Inflammatory Mediators in Epilepsy: A Systematic Review of Its Molecular Basis and Clinical Applications.

Authors:  Giorgio Costagliola; Greta Depietri; Alexandre Michev; Antonella Riva; Thomas Foiadelli; Salvatore Savasta; Alice Bonuccelli; Diego Peroni; Rita Consolini; Gian Luigi Marseglia; Alessandro Orsini; Pasquale Striano
Journal:  Front Neurol       Date:  2022-03-11       Impact factor: 4.003
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.